Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Inventory: 2023-2024

Historic Inventory for Seres Therapeutics (MCRB) over the last 1 years, with Jun 2024 value amounting to $53.0 million.

  • Seres Therapeutics' Inventory rose 892.45% to $53.0 million in Q2 2024 from the same period last year, while for Jun 2024 it was $53.0 million, marking a year-over-year increase of 892.45%. This contributed to the annual value of $29.6 million for FY2023, which is N/A change from last year.
  • As of Q2 2024, Seres Therapeutics' Inventory stood at $53.0 million, which was up 26.26% from $42.0 million recorded in Q1 2024.
  • In the past 5 years, Seres Therapeutics' Inventory ranged from a high of $53.0 million in Q2 2024 and a low of $5.3 million during Q2 2023.
  • For the 2-year period, Seres Therapeutics' Inventory averaged around $29.7 million, with its median value being $29.6 million (2023).
  • Data for Seres Therapeutics' Inventory shows a peak YoY surged of 892.45% (in 2024) over the last 5 years.
  • Quarterly analysis of 2 years shows Seres Therapeutics' Inventory stood at $29.6 million in 2023, then spiked by 892.45% to $53.0 million in 2024.
  • Its last three reported values are $53.0 million in Q2 2024, $42.0 million for Q1 2024, and $29.6 million during Q4 2023.